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Abstract 25 
Dendritic cells (DCs) are specialized antigen presenting cells that instruct T cell responses through 26 
sensing environmental and inflammatory danger signals. Maintaining the homeostasis of the multiple 27 
functionally distinct conventional dendritic cells (cDC) subsets that exist in vivo is crucial for 28 
regulating immune responses, with changes in numbers sufficient to break immune tolerance. Using 29 
Ptpn22-/- mice we demonstrate that the phosphatase PTPN22 is a highly selective, negative regulator 30 
of cDC2 homeostasis, preventing excessive population expansion from as early as 3 weeks of age. 31 
Mechanistically, PTPN22 mediates cDC2 homeostasis in a cell intrinsic manner by restricting cDC2 32 
proliferation. A single nucleotide polymorphism, PTPN22R620W, is one of the strongest genetic risk 33 
factors for multiple autoantibody associated human autoimmune diseases. We demonstrate that cDC2 34 
are also expanded in mice carrying the orthologous PTPN22619W mutation. As a consequence, cDC2 35 
dependent CD4+ T cell proliferation and T follicular helper cell responses are increased. Collectively, 36 
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our data demonstrate that PTPN22 controls cDC2 homeostasis, which in turn ensures appropriate 37 
cDC2-dependent T cell responses under antigenic challenge. Our findings provide a link between 38 
perturbations in DC development and susceptibility to a broad spectrum of PTPN22R620W associated 39 
human autoimmune diseases. 40 
 41 
1 Introduction 42 
Dendritic cells (DCs) are specialized antigen presenting cells that sense danger signals and instruct T 43 
cell responses(Merad et al., 2013). Distinct subsets of DCs exist in vivo, broadly divided into 44 
conventional (cDC) and plasmacytoid (pDC) subsets. In mice, cDCs (CD11c+MHCII+) are sub-45 
divided into functionally distinct phenotypes defined as cDC1 (CD8+IRF8+XCR1+Clec9a+CD24+) 46 
and cDC2 (IRF4+CD11b+SIRPα+) whilst in humans the equivalent DC subsets are defined by 47 
expression of CD8+IRF8+XCR1+Clec9a+CD141+ (cDC1) and IRF4+CD1c+ (cDC2)(Tamura et al., 48 
2005; Merad et al., 2013; Collin and Bigley, 2018; Dress et al., 2018). Functionally, cDC1 cross-49 
present exogenous antigens to activate CD8+ T cells and can promote IL-12 dependent Th1 50 
responses(Maldonado-López et al., 1999; den Haan et al., 2000; Mashayekhi et al., 2011; Merad et 51 
al., 2013). In comparison, cDC2s are potent activators of CD4+ T cells(Dudziak et al., 2007). Under 52 
polarizing inflammatory conditions, cDC2 induce Th2 responses in the lung(Williams et al., 2013; 53 
Tussiwand et al., 2015), drive Th17 responses through IL-23 secretion(Denning et al., 2011; Lewis et 54 
al., 2011; Kinnebrew et al., 2012; Persson et al., 2013; Satpathy et al., 2013; Schlitzer et al., 2013; 55 
Schreiber et al., 2013), and initiate SIRPα dependent induction of T follicular helper cells (TFH) and 56 
germinal center (GC) formation(Yi et al., 2015).  57 
Maintenance of cDC homeostasis is crucial for regulating immune responses, with deregulation 58 
resulting in infection and autoimmunity(Ashany et al., 1999; Birnberg et al., 2008; Ohnmacht et al., 59 
2009; Cai et al., 2019). This control of cDC homeostasis is mediated by a number of factors that 60 
drive cDC differentiation, proliferation, and survival or apoptosis(Dress et al., 2018). Differentiation 61 
of cDCs is initiated within the bone marrow where common DC precursors (CDP) transition to an 62 
intermediate preDC developmental stage (including pre-cDC1 and pre-cDC2s)(Naik et al., 2007; 63 
Onai et al., 2007; Liu et al., 2009; Sathe et al., 2014; Swiecki et al., 2014; Schlitzer et al., 2015), with 64 
terminal differentiation into cDC1 and cDC2 subsets occurring in the periphery(Maraskovsky et al., 65 
2000); cDC1 and cDC2s are then dependent on Flt3L for their development and 66 
proliferation(Maraskovsky et al., 2000). Furthermore, local signals transduced through 67 
NOTCH2(Lewis et al., 2011; Satpathy et al., 2013) or LTβR(Luther et al., 2000; Kabashima et al., 68 
2005) contribute to cDC homeostasis within specific tissue niches. Indeed, LTβR signalling is 69 
particularly important for inducing cDC2 proliferation within secondary lymphoid organs 70 
(SLOs)(Luther et al., 2000; Kabashima et al., 2005).  71 
PTPN22 encodes a tyrosine phosphatase that negatively regulates immune receptor activation. It 72 
functions by dephosphorylating Src and Syk family kinases operating proximal to immune-receptors 73 
such as TCR, BCR, and LFA-1(Rieck et al., 2007; Dai et al., 2013; Salmond et al., 2014; Burn et al., 74 
2016; Sanchez-Blanco et al., 2018). PTPN22 also operates in a phosphatase independent manner, 75 
directly binding to TRAF3 in myeloid cells and promoting type 1 interferon dependent TRAF3 76 
ubiquitination(Wang et al., 2013). Regarding its contribution to disease, a C1858T single nucleotide 77 
polymorphism within PTPN22 (encoding R620W) is one of the strongest genetic risk factors outside 78 
the HLA for the development of multiple autoimmune diseases, including rheumatoid arthritis, type I 79 
diabetes, and lupus(Burn et al., 2011). Investigations into the functional effects of this variant have 80 
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demonstrated that PTPN22R620W confers a missense mutation in the P1 domain of the PTPN22 PEST 81 
region, resulting in reduced binding to the negative regulatory tyrosine kinase Csk, and 82 
TRAF3(Fiorillo et al., 2010; Wang et al., 2013). However, the consequence of PTPN22R620W on 83 
immune function remains unclear, appearing to depend on the cellular context and signaling pathway 84 
under investigation. Indeed, both gain- and loss-of-phosphatase function effects of PTPN22R620W 85 
have been described(Rawlings et al., 2015).  86 
Using Ptpn22 mutant mice, we describe PTPN22 as key mediator in the restriction of cDC2 87 
populations. Perturbation of cDC2 homeostasis is phenocopied in mice carrying the human 88 
autoimmune associated variant, translating to accentuated cDC2-driven T cell responses upon 89 
antigenic challenge. Based on these data, we propose that disruption of cDC homeostasis by 90 
PTPN22R620W genetic polymorphism contributes to the breeching of immune tolerance during the 91 
earliest phase of autoimmunity. 92 
  93 
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2 Methods 94 
2.1 Mice 95 
Ptpn22-/- mice and Ptpn22R619W mutant mice were backcrossed >10 generations to the C57BL/6 96 
strain, their generation is described in(Brownlie et al., 2012; Dai et al., 2013). Mice were age and 97 
sex-matched within each individual experiment and were used at either 2-4 months or as otherwise 98 
indicated. Ptpn22fl/+ mice were bred with PC3-Cre mice and backcrossed to C57BL/6 mice for four 99 
generations and were used between 8-12 weeks of age. OT-II TCR transgenic CD45.1, CD45.1, and 100 
CD45.1/2 transgenic mice were used between 8-16 weeks of age. Where indicated, tissue was 101 
obtained, shipped on ice and processed within 24 hours from mice bred and maintained at Edinburgh 102 
University under U.K. Home Office approved guidelines. Mice were age and sex-matched within 103 
each individual experiment and were used at either 2 months or 6 months of age. Unless otherwise 104 
stated mice were maintained under specific pathogen free (SPF) conditions at King’s College London 105 
Facility according to UK Home Office approved protocols. 106 
2.2 Tissue processing  107 
Spleens and LNs were injected with RPMI containing Liberase-TL (0.1mg/ml; Roche) and DNase 1 108 
(0.1mg/ml; Sigma), and incubated at 37°C 5% CO2 for 30 minutes. EDTA (10mM) was added for the 109 
final 5 minutes of the 30-minute incubation. Spleen single cell suspensions were RBC lysed 110 
(Biolegend). Blood obtained by cardiac puncture was incubated at room temperature 1 hour and 111 
serum separated following centrifugation. Bone marrow was flushed from the femurs and tibias of 112 
WT and Ptpn22-/- mice, RBC lysed and pelleted. Cell suspensions were prepared from the small 113 
intestine after removal of Peyer's patches and fat. Intestines were opened longitudinally, washed of 114 
fecal contents, cut into 5 cm pieces and incubated in HBSS medium (Life Technologies) with 2 mM 115 
EDTA for 20 minutes at 37°C with rotation. Tissue pieces were washed in HBSS medium, minced 116 
and incubated in HBSS medium + 2% FBS with collagenase VIII (100U/ml, Sigma, C2139) and 117 
DNAse1 (20µg/ml) at 37 °C for 40 min with rotation. Cell suspensions was passed through a 40µm 118 
filter and pelleted at 350g 15mins 4C. Cells were then stained for flow cytometry.  119 
Cells from all tissues were resuspended in PBS and live cells counted by trypan blue discrimination.  120 
2.3 Bone marrow chimeras 121 
CD45.1 or CD45.1/2 mice were haematopoietically-lethally irradiated by exposure to 9Gy for 6 122 
minutes. 6 hours later, bone marrow cells (2.5–5×106 cells in 100µl) were i.v transferred into 123 
irradiated recipients. Chimeric mice were analyzed 8 weeks after bone marrow transfer (unless 124 
otherwise indicated). As a control for complete replacement of recipient bone marrow, CD45.1+ 125 
recipients received 100% CD45.2+ C57BL/6 bone morrow.   126 
2.4 T cell adoptive transfers 127 
Total CD4+ T cells from the lymph nodes (LN) and spleens of 8-16-week old WT OT-II mice were 128 
isolated using CD4+ MACS negative selection kit according to manufacturer’s instructions (Miltenyi 129 
Biotech). Purity of CD4+ T cells was determined by flow cytometry (routinely 90-95%). CD4+ T 130 
cells isolated from CD45.1 WT OT-II mice were labelled with cell trace violet (CTV; 2µM; 131 
Invitrogen) at 2x107 cells/ml in PBS for 20 minutes at 37°C, and excess CTV quenched in complete 132 
medium for 20 minutes at 37°C. Recipient mice received 0.5-1x106 CTV+CD4+OT-II T cells 133 
resuspended in 100µL PBS i.v. The following day T cell recipient mice were immunised i.v with 134 
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33D1-ovalbumin (200µg/mouse)(Neubert et al., 2014) in the presence or absence of sheep RBC 135 
(SRBC; Antibodies-online.com; 20x107 cells/mouse). After 3 days spleens were assessed by flow 136 
cytometry for CTV dilution and CXCR5+ PD1+ TFH within live, singlet, CD45.1+, CD4+, Vα2Vβ5+ 137 
cell gate.  138 
2.5 DC and CD4+ T cell co-culture 139 
CD4+ T cells isolated from OT-II mice were labeled with cell trace violet (CTV) (2 µM; Invitrogen) at 140 
2x107 cells/ml in PBS for 20 minutes at 37°C, and excess CTV quenched in complete medium for 20 141 
minutes at 37°C. T cells were co-cultured with isolated DC at a 2:1 T cell to cDC ratio 2x106:1x106 142 
cells/ml in round bottom 96-well plates in the presence or absence of 33D1-ovalbumin (10 µg/ml) or 143 
anti-DEC205-ovalbumin (10 µg/ml) and cells were co-cultured for 6 days at 37°C 5% CO2. At day 6 144 
cells were stained with fixable viability dye eFluor-506 (eBioscience), anti-CD3ε and anti-CD4.  CTV 145 
dilution gated on live, singlet, CD3+CD4+ T cells was assessed by flow cytometry. 146 
2.6 BrdU labeling  147 
3 days prior to analysis mice were i.p injected daily with BrDU (10mg/kg) and maintained ad libitum 148 
on drinking water containing BrdU (0.5mg/ml).  149 
2.7 Flt3 Ligand Bone Marrow DC 150 
Bone marrow was RBC lysed and cells seeded at 1x106 cells/ml in 6-well tissue culture plates in 151 
RPMI-1640 supplemented with glutamax, 10% heat-inactivated FBS, β-mercaptoethanol (50µM), 152 
penicillin/streptomycin (100µg/ml), and HEPES 1mM (Sigma) and Flt3L (200ng/ml; Biolegend). 153 
Flt3L-BMDCs were cultured for 8 days at 37°C and 5% CO2. At day 8 non-adherent and adherent 154 
Flt3L-BMDC were harvested with trypsin-EDTA (Sigma) incubated for 2 minutes at room 155 
temperature. Cells were washed and live cells counted by trypan blue discrimination and seeded at 156 
1x106 cells/ml on 96-well flat bottom plates for 48 hours in the presence or absence of anti-LTβR 157 
(2µg/ml; 3C8; AdipoGen).   158 
2.8 Flow cytometry 159 
Fluorochrome or biotin-conjugated antibodies were used to stain single cell suspensions for flow 160 
cytometry. Fc receptors were blocked with anti-mouse CD16/CD32 (93; Biolegend) and dead cell 161 
exclusion was performed using Fixable Viability Dye (eBioscience). FACS buffer was made of PBS 162 
with 1% bovine serum albumin (Sigma) and 2mM EDTA (Sigma). For BrDU staining following 163 
surface staining, splenocytes were fixed and permeabilised using APC-BrDU Flow Kit (BD 164 
Pharmingen). Cells were acquired using BD Fortessa or FACSCanto II flow cytometers. Performed 165 
in the Biomedical Research Centre Flow Core Facility (Guy’s and St Thomas’ NHS Foundation 166 
Trust and King’s College London). Flow cytometry gates were determined by fluorescence minus 167 
one controls. Flow cytometry analysis was performed using FlowJo software (TreeStar; 10.5.3). 168 
2.9 Flow cytometry monoclonal antibodies specific to mouse 169 
CD3ε (145-2C11), CD4 (GK1.5), CD8a (53-6.7), CD11b (M1/70), CD11c (N418), CD24 (M1/69), 170 
CD45R/B220 (RA3-6B2), CD45.1 (A20), CD45.2 (104), CD86 (GL-1), CD103 (2E7), CD172a 171 
(SIRP alpha; P84), CD279 (PD1; 29F.1A12), CXCR5 (L138D7), I-Ab (AF6-120.1), TCR Vα2 172 
(B20.1), TCRVb5 (MR9-4), CD16/32 (93), Ki67 (16A8), Ly-6G/Ly-6C (RB6-8C5), Ly-6G (1A8), 173 
(Ly6C (AL-21), Ter-119 (TER-119), NK-1.1 (PK136), CD19 (6D5), DCIR2 (33D1), cKit (2B8), 174 
Flt3 (A2-F10), LTβR (5G11) that were bought from Biolegend, eBioscience, or BD. 175 
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2.10 Immunofluoresence staining 176 
Spleens were harvested into RPMI and 10% FBS and dried prior to being frozen at -80°C in OCT. 177 
10µM sections were generated and mounted onto slides using a Leica cryostat. Sections were fixed 178 
with 4% PFA for 15 minutes and washed with PBS. Sections were blocked for 30 minutes in 179 
blocking buffer (PBS + 2% FBS, rat serum (1 in 200) and anti-CD16/CD32 (1 in 200) for 30 minutes 180 
at room temperature. Sections were stained for 1 hour at room temperature with B220-FITC and 181 
33D1-Alexa-647 in PBS 2% FBS. Slides were washed 3 times with PBS prior to mounting in 182 
fluorescence mounting media (DAKO). Images were collected using an Olympus IX83 inverted 183 
microscope and image processing was performed using Fiji.  184 
2.11 Real-time PCR 185 
Total RNA was extracted from FACS isolated cDC2 using TRIzol reagent. Equal amounts of mRNA 186 
(determined by nanodrop; ThermoScientific) were reverse transcribed to produce cDNA using first 187 
strand cDNA synthesis using random hexamers. Gene expression was measured by SYBR Green 188 
quantitative real-time PCR using primers: Bcl2 forward, TGAGTACCTGAACCGGCATCT, Bcl2 189 
reverse, GCATCCCAGCCTCCGTTAT; Bim forward, GGCCCCTACCTCCCTACA, Bim reverse, 190 
GGGGTTTGTGTTGATTTGTCA; Trim2 forward, TTTCCATAATCACTCTGTCAAGGT, Trim2 191 
reverse, CCATTGGAGCCAAACTTCA; Gapdh forward, ACCACAGTCCATGCCATCAC Gapdh 192 
reverse, TCCACCACCCTGTTGCTGTA. Reactions were run using ABI Prism 7700 Sequence 193 
Detection System (Applied Biosystems). Ct values were determined with SDS software (Applied 194 
Biosystems) and gene expression levels were determined according to the dCt method (relative 195 
abundance = 2(−dct) and normalized to GAPDH housekeeper).  196 
2.12 Serum Flt3L 197 
Blood obtained by cardiac puncture was incubated at room temperature 1 hour and serum separated 198 
following centrifugation. Serum Flt3 Ligand was determined by Mouse/Rat Quantikine ELISA 199 
(R&D Systems) according to manufacturer’s protocol and detected using Victor 1420 multilabel 200 
counter (Perkin Elmer). 201 
2.13 Statistical analysis 202 
GraphPad Prism software was used for statistical analysis by unpaired or paired T-test. P values less 203 
than 0.05 were considered significant; NS=not significant, *p<0.05, ** p<0.01, ***p<0.001, 204 
****p<0.0001. 205 
 206 
3 Results  207 
3.1 PTPN22 is a negative regulator of cDC2 homeostasis 208 
Ptpn22-/- mice have a well-characterized age dependent increase in effector/memory T lymphocytes 209 
and spontaneous GC production. However, the effect of PTPN22 on myeloid lineages is not 210 
understood. To address this, we examined if myeloid cell lineages were altered in mice lacking 211 
PTPN22. We detected a similar frequency of monocytes, macrophages, and neutrophils 212 
(Supplementary Figure 1A-C) within the spleens of WT and Ptpn22-/- mice. In contrast, analysis of 213 
the splenic cDC compartment revealed that both the proportion and number of cDCs was increased in 214 
Ptpn22-/- mice compared to WT (Figure 1A-B). Further phenotyping of cDC1 and cDC2 subsets 215 
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revealed that the proportion of cDC2 was increased in Ptpn22-/- mice, whereas the proportion of 216 
cDC1 was decreased (Figure 1A and C). By comparing the number of splenic cDC1s and cDC2s 217 
within WT and Ptpn22-/- mice we found that changes in cDC subset proportions were due to selective 218 
expansion of the cDC2 subset and not loss of cDC1 cells (Figure 1D). Indeed, expansion of splenic 219 
cDC2s occurred within the bona fide DCIR2(33D1)+ESAM+CD4+CCR2- cDC2 subset, whereas 220 
numbers of the ‘monocyte-like’ DCIR2(33D1)-ESAM-CD4-CCR2+/- DCs were similar (Figure 1E,F 221 
and Supplementary Figure 1D-F). Analyzing the kinetics of cDC2 expansion demonstrated that 222 
perturbation of cDC2 homeostasis could be detected as early as 3 weeks (Figure 1G,H), increasing 223 
further as the mice age (Supplementary Figure 1G). We confirmed these findings in WT and Ptpn22-224 
/- mice bred and maintained in an independent animal facility suggesting that cDC2 expansion was 225 
unlikely to be due to facility-associated environmental factors (Supplementary Figure 1H and I).  226 
To examine if cDC homeostasis was altered in other lymphoid tissues, we examined cDC 227 
populations within skin draining lymph nodes (sdLN), and found that Ptpn22-/- mice displayed 228 
expanded resident, but not migratory cDC2. Once again similar numbers of cDC1 were observed 229 
within both migratory and resident cDC populations (Figure 1I-K). A similar phenotype was 230 
documented within the mesenteric lymph nodes, wherein resident CD11b+ CD103- cDC2 were 231 
expanded, while CD103+ resident cDCs and all migratory (IAb high) cDC subsets assessed were 232 
unaltered (Supplementary Figure 1J-L). Furthermore, in line with Ptpn22 not regulating migratory 233 
cDC2, cDC2 positioning within the spleen bridging channels appeared similar between WT and 234 
Ptpn22-/- mice (Supplementary Figure 1M). Together, we conclude that PTPN22 regulates resident 235 
DC2 homeostasis within secondary lymphoid organs (SLOs).  236 
3.2 PTPN22 regulates cDC2 homeostasis via a DC intrinsic mechanism  237 
Given its broad expression in multiple hematopoietic lineages, PTPN22 has the potential to control 238 
cDC2 homeostasis through DC intrinsic or DC extrinsic mechanisms. To investigate this, we 239 
generated Ptpn22-/- CD45.2: WT CD45.1 mixed bone marrow chimeras and found that CD45.2 240 
Ptpn22-/- bone marrow out-competed WT CD45.1 in the generation of cDC2 (Figure 2A-D), whereas 241 
no change was observed in the ratio of Lin+ cells (Supplementary Figure 2A). Consistent with our 242 
previous observations, generation of cDC1 was unaffected by genotype, further supporting a role for 243 
PTPN22 as a selective, DC intrinsic regulator of cDC2 homeostasis. PTPN22 regulates T cell 244 
homeostasis(Hasegawa et al., 2004), raising the possibility of an indirect cDC2 phenotype driven by 245 
enhanced T cell activation in PTPN22:WT chimeras. Therefore, we examined if lineage specific 246 
deletion of Ptpn22 within the T cell compartment would have an impact on cDC2 populations. We 247 
detected no differences in cDC2 expansion in either mice with T cell restricted Ptpn22-/- 248 
(Supplementary Figure 2B) or between chimeras harboring PTPN22 sufficient or deficient T cells 249 
(Figure 2E), indicating that deficiency of Ptpn22 exclusively in T cells was not sufficient to perturb 250 
cDC homeostasis.  251 
Finally, we determined if the Ptpn22-/- environment (via an indirect effect on stroma), contributed to 252 
cDC2 expansion. WT CD45.1 bone marrow was transferred into non-irradiated WT and Ptpn22-/- 253 
CD45.2 mice. After 6 days we observed no difference in CD45.1 cDC2 numbers developing within 254 
either WT or Ptpn22-/- mice (Figure 2F,G). This result is consistent with previous reports establishing 255 
that PTPN22 expression is restricted to hematopoietic cell lineages(Cohen et al., 1999; He et al., 256 
2014). Together, these data suggest that PTPN22 regulates cDC2 homeostasis via a cDC intrinsic 257 
mechanism.  258 
3.3 PTPN22 regulates cDC2 homeostasis after pre-cDC development 259 
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Homeostasis of cDC in SLOs is controlled by multiple factors including differentiation of bone 260 
marrow precursors in response to Flt3L, duration of cDC survival, proliferation of incoming 261 
precursor cDCs, and the turnover of a small subset of cDCs within SLOs(Merad et al., 2013). We 262 
therefore aimed to examine how PTPN22 might regulate cDC2 development. Firstly, we observed no 263 
PTPN22 dependent difference in bone marrow or splenic common DC precursors (CDP) or preDC 264 
cells, indicating that PTPN22 operated post pre-cDC development (Supplementary Figure 3A-C).  265 
Secondly, as cDC1 and cDC2 are dependent on Flt3L for their differentiation we tested if PTPN22 266 
controls Flt3L dependent cDC2. We observed similar Flt3R expression on ex vivo WT and Ptpn22-/- 267 
cDC1 and cDC2 (Supplementary Figures 3D-E), as well as similar concentrations of serum Flt3L in 268 
vivo (Supplementary Figure 3F). To compare Flt3L dependent cDC2 development, we cultured WT 269 
and Ptpn22-/- bone marrow in vitro with Flt3L. However, no significant changes in cDC2 270 
development were observed (Figure 3A). We then assessed if PTPN22 altered cDC2 survival by 271 
comparing the expression of survival genes Bcl2, Bim, and Trim in FACS sorted cDC2. Once again 272 
we observed no differences between WT and Ptpn22-/- cDC2 (Supplementary Figure 3G). 273 
Furthermore, no differences were observed between splenic WT and Ptpn22-/- cDC2 acquiring an 274 
apoptotic phenotype (Annexin V+) as a consequence of a 24-hour culture in vitro (Supplementary 275 
Figure 3H). Based on these data, we reasoned that differences in cell survival were unlikely to be a 276 
major mechanism mediating cDC2 expansion in Ptpn22-/- mice.  277 
3.4 PTPN22 negatively regulates cDC2 proliferation 278 
Having excluded a role for PTPN22 in regulating DC precursor development, Flt3L dependent 279 
differentiation or cDC2 survival, we next addressed if PTPN22 might control cDC2 proliferation. To 280 
test this hypothesis, we examined the in vivo effects of 5-flurouracil (5-FU), a pyrimidine analogue 281 
that inhibits cell proliferation(Longley et al., 2003). Previous reports have demonstrated that 3 days 282 
post-5-FU administration DC populations are significantly reduced within the spleen, indicative of 283 
rapid turnover of DCs in vivo(Zhan et al., 2016). The difference in cDC2 expansion between WT and 284 
Ptpn22-/- mice was abrogated 3 days after treatment with 5-FU, demonstrating that PTPN22 mediated 285 
expansion of cDC2 is indeed dependent on proliferation (Figure 3B). Consistent with our data using 286 
5-FU, administration of thymidine analogue BrDU, which incorporates into proliferating cells, 287 
demonstrated that the Ptpn22-/- cDC2 population was significantly expanded within the BrDU+ 288 
(proliferating), but not the BrDU- (non-proliferating) population (Figure 3C,D). Furthermore, Ki67 289 
and DAPI staining confirmed enhanced proportions of cDC2 undergoing cell cycling (Figure 3E,F 290 
and Supplementary Figure 3I). Likewise, cell cycle analysis of competitive bone marrow chimeras 3 291 
weeks post transfer also demonstrated a significant increase in the proportion of cycling Ptpn22-/- 292 
cDC2 when compared to WT controls (Supplementary Figure 3J). Taken together, these data support 293 
the notion that PTPN22 controls cDC2 homeostasis by restricting cDC2 proliferation. 294 
3.5 Ptpn22619W confers expansion of ESAM+CD4+ cDC2s  295 
The human PTPN22R620W polymorphism is one of the highest-ranking genetic risk factors for the 296 
development of multiple autoimmune diseases outside MHC loci (Burn et al., 2011; Stanford and 297 
Bottini, 2014). Given that PTPN22 regulates the expansion of cDC2s, we set out to examine whether 298 
the autoimmune associated variant was capable of mediating similar effects. To address this, we 299 
enumerated splenic cDC subsets in mice expressing the R620W orthologue, Ptpn22619W. In 300 
comparison to Ptpn22619R, mice carrying Ptpn22619W also displayed expansion of splenic cDC2s, 301 
which, like Ptpn22-/- mice, occurred specifically within the ESAM+CD4+ DC2 subset (Figure 4A,B). 302 
Furthermore, the magnitude of cDC2 expansion was similar to Ptpn22-/- mice when compared to WT 303 
(1.5-fold vs 2-fold respectively). This demonstrated that the autoimmune associated PTPN22 variant 304 
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is also capable of regulating cDC2 homeostasis, operating as a loss-of-function mutant in this 305 
context.  306 
3.6 Ptpn22619W enhances T cell proliferation and generation of TFH  307 
PTPN22R620W is a risk allele associated with multiple autoantibody associated autoimmune diseases. 308 
Splenic cDC2 are essential initiators of TFH differentiation, leading to GC formation, and high-309 
affinity antibody production (Yi et al., 2015; Briseño et al., 2018). Interestingly, with age Ptpn22-/- 310 
and Ptpn22619W mice develop spontaneous GC, and enhanced serum IgG levels (Hasegawa et al., 311 
2004; Dai et al., 2013; Maine et al., 2014). Accordingly, we addressed whether expansion of splenic 312 
cDC2 in Ptpn22619W mice was sufficient to alter cDC2 dependent T cell activation and TFH induction 313 
in vivo. To evaluate cDC2 dependent antigen specific responses in vivo we administered 33D1-OVA 314 
conjugates to selectively target the cDC2 subset (Supplementary Figure 4)(Dudziak et al., 2007). WT 315 
and Ptpn22619W mice received CD45.1 OT-II CD4+ T cells and were immunised with 33D1-OVA in 316 
the presence of SRBCs to promote cDC2 activation (Figure 4C), and potentiate OT-II proliferation 317 
and TFH responses (Figures 4D,E)(Yi et al., 2015; Briseño et al., 2018). When compared to WT 318 
recipients, Ptpn22619W cDC2 expansion was sufficient to enhance OT-II proliferation in vivo (Figure 319 
4F). Furthermore, we observed that the proportion and number of splenic OT-II TFH that develop 320 
within Ptpn22619W recipients was significantly enhanced compared to WT following 33D1-321 
OVA/SRBC immunisation (Figure 4G,H). Our previous investigations demonstrate that Ptpn22 is 322 
dispensable for antigen uptake and presentation (Clarke et al., 2017). Furthermore, the in vitro data 323 
presented here indicate that differences in OT-II proliferation are due to altered cDC2 homeostasis, 324 
(specifically the number of cDC2 cells), rather than a cell intrinsic difference in Ptpn22 variant 325 
cDC2. When total, unmanipulated splenic cDC are FACS isolated (preserving the cDC2 expansion 326 
observed in vivo) and co-cultured with OT-II in the presence of 33D1-OVA, Ptpn22-/- are able to 327 
potentiate OT-II T cell proliferation (Supplementary Figure 4B). Conversely, when cDC2 are FACS 328 
isolated (normalizing cDC2 numbers) and cultured in the same manner, WT and Ptpn22-/- cDC2 are 329 
capable of inducing OT-II proliferation to the same extent. Furthermore, no difference in OT-II 330 
proliferation is observed when co-cultured with FACS isolated cDC1 in the presence of DEC205-331 
OVA (Supplementary Figure 4D). Together, these data reveal that Ptpn22619W mediated cDC2 332 
expansion is sufficient to deregulate T cell activation in response to non-self-antigens, and is likely to 333 
contribute to the promotion of TFH responses in vivo alongside previously reported T cell and B cell 334 
intrinsic effects (Dai et al., 2013; Maine et al., 2014).  335 
 336 
4 Discussion  337 
Here, we provide evidence that the autoimmune disease-associated phosphatase PTPN22 is a 338 
regulator of cDC2 homeostasis. Loss-of-function mutants of PTPN22 result in cDC2 expansion 339 
through mechanisms that are DC intrinsic, enhancing cDC2 proliferation. Thus, PTPN22 appears to 340 
be a selective regulator of cDC2 homeostasis. Furthermore, cDC2 expansion conferred by the 341 
autoimmune associated Ptpn22619W variant resulted in aberrant cDC2 dependent TFH induction in 342 
vivo. Our data therefore uncover a novel mechanism by which TFH expansion, first reported in 343 
Ptpn22 deficient mice, may be underpinned by a specific cDC2 phenotype.  344 
The precise mechanisms by which Ptpn22 mediates selective expansion of cDC2 remains to be 345 
determined. However, we now know that Ptpn22 deficiency mediates the expansion of ESAM+CD4+ 346 
cDC2 (Figure 1E), a cDC2 subset that is known to be dependent on LTβR for their proliferation 347 
(Satpathy et al., 2013). Furthermore, splenic Ptpn22-/- cDC2 were more proliferative ex vivo (Figure 348 
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3B-F). Consistent with our data, Ltβr-/- splenic cDC2s are less proliferative, resulting in decreased 349 
cDC2 numbers(Kabashima et al., 2005). Indeed, our preliminary experiments indicate that Ptpn22 350 
may control LTβR mediated cDC2 proliferation. LTβR agonist treatment of Ptpn22-/- Flt3L-BMDC 351 
increased cDC2 numbers compared to WT (Supplementary Figure 5A,B), whilst no difference in cell 352 
surface LTβR expression was observed on ex vivo or in vitro generated Flt3L BMDC (Supplementary 353 
Figure 5D-F). In addition, phenotypes described in Relb-/- mice, further support the hypothesis that 354 
PTPN22 may regulate LTβR dependent cDC2 proliferation. LTβR activates canonical pathway and 355 
non-canonical NFκB signaling, resulting in RelB translocation(Bista et al., 2010). Within Relb-/- 356 
mice, there is a severe reduction in splenic and LN resident (but not migratory) cDC2, from as early 357 
as 3 weeks of age, whereas cDC1 numbers are unaffected(Briseño et al., 2017), and Flt3L dependent 358 
DC development is unaffected by Relb-/-. In addition, despite lamina propria DC being dependent on 359 
Notch2 and LTβR signaling, Relb-/- does not affect CD11b+ DC subsets at this location (Satpathy et 360 
al., 2013; Briseño et al., 2017). In keeping with these reports, we observed no difference in lamina 361 
propria CD11b+ DC subsets between WT and Ptpn22-/- mice (Supplementary Figure 6). Therefore, in 362 
both Relb-/- and Ptpn22-/- mice the same cDC2 populations are disrupted, being decreased in Relb-/- 363 
and increased in Ptpn22-/-, with both occurring within a 3-week time frame. In contrast, due to 364 
differences in the specific cDC2 phenotypes reported, our data do not support a role for PTPN22 in 365 
regulating IRF4(Suzuki et al., 2004), KLF4 (Tussiwand et al., 2015), or NOTCH2(Lewis et al., 2011; 366 
Satpathy et al., 2013) dependent cDC2 development. As such, our data are consistent with a model 367 
whereby PTPN22 may function to negatively regulate LTβR signaling, limiting RelB translocation to 368 
control cDC2 homeostasis. 369 
One question that our data raise, is why and how Ptpn22 selectively regulates cDC2 homeostasis? 370 
One explanation might be the differential expression of Ptpn22 in DC subsets, which is substantially 371 
higher in cDC2 than cDC1 or pDC (ImmGen); implying that the effects of Ptpn22 deficiency are 372 
likely to be greatest in cells with the highest expression. An alternate explanation is that Ptpn22 373 
regulates signaling pathways specifically required for cDC2 but not cDC1 development. In line with 374 
this, our data demonstrate no defect in pathways required by both cDC1 and cDC2, since both 375 
precursor cDC development (Supplementary Figure 3A-C) and Flt3L responsiveness (Supplementary 376 
Figure 3A) remain intact in Ptpn22-/- mice. Conversely, proliferation was enhanced specifically in 377 
Ptpn22-/- cDC2 population (Figure 3), indicating that Ptpn22 may operate to restrain cDC2 378 
proliferation in response to signals required for cDC2 turnover. One factor known to mediate the 379 
proliferation of a small subset of cDC2 is LTbR, and Ptpn22 may be involved in regulating this 380 
proliferative signal in vivo. Alternatively, Ptpn22 may regulate the signaling of an as yet to be 381 
identified pathway that is also required for cDC2 proliferation. Further detailed investigation is 382 
required to uncover the mechanistic basis for the pathway(s) regulated by Ptpn22 in this context.  383 
PTPN22R620W is one of the strongest autoimmune disease associated genetic risk factors. We 384 
demonstrate that cDC2 homeostasis is disrupted in mice that express the orthologue of the human 385 
autoimmune associated variant (Figure 4A,B). To our knowledge, this is the first description of cDC 386 
homeostasis being regulated by an autoimmune associated genetic risk allele. Our data therefore 387 
provide a link between genetic and environmental risk and the breakdown of immune tolerance that 388 
leads to autoimmunity. Changes to cDC homeostasis have been described within autoimmune 389 
diseases for which PTPN22R620W is a risk factor. In type 1 diabetes the effector phase of murine type I 390 
diabetes is characterised by cDC2 expansion(Price and Tarbell, 2015).  Furthermore, in humans with 391 
rheumatoid arthritis (RA), cDC2 are decreased within the blood, but expanded within the lymph 392 
nodes(Ramwadhdoebe et al., 2014), and the RA synovium is enriched with RelB+ DCs(Pettit et al., 393 
2000). Together, suggesting an association between the enhanced presence of cDC2s within SLOs 394 
and tissue and the risk of developing autoimmune disease.  Therefore, a failure to maintain cDC 395 
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homeostasis, as conferred by the PTPN22 risk allele, may be a factor altering the downstream 396 
immune responses that ultimately lead to autoimmunity 397 
Although we accept that the difference between WT and Ptpn22 variant cDC2 populations may 398 
appear modest, over the lifetime of a human, these changes could have significant functional impact 399 
over the decades that precede autoimmune disease onset. In the context of non-self cDC2-targeted 400 
antigen, Ptpn22619W dependent expansion of cDC2 was sufficient to enhance T cell proliferation and 401 
TFH expansion following GC promoting SRBC stimulation (Figure 4F,G). Activation of ESAM+ 402 
cDC2 is one of the earliest events in splenic GC formation leading to high-affinity antibody 403 
production(Yi et al., 2015; Briseño et al., 2018). With ageing, PTPN22 mutant mice develop many 404 
hallmarks of autoimmunity including increased effector T cells, activated B cells and higher 405 
immunoglobulin and autoantibody titres(Hasegawa et al., 2004; Dai et al., 2013). Furthermore, 406 
humans carrying the PTPN22620W variant have an increased risk of developing autoimmune diseases 407 
that are almost exclusively associated with autoantibody production(Burn et al., 2011; Stanford and 408 
Bottini, 2014). PTPN22 has been reported to regulate TFH(Maine et al., 2014) cells, GC formation, 409 
and antibody production(Dai et al., 2013) in part via T cell and B cell intrinsic effects. Although our 410 
data do not address self-reactivity, they do indicate that changes conferred by Ptpn22R619W altering 411 
cDC2 homeostasis, could, alongside T and B intrinsic effects, also contribute to perturb the GC 412 
reaction over time. Age is an important risk factor for autoimmune disease onset due to declining 413 
immune competence and impaired immune tolerance check points(Goronzy and Weyand, 2012). In 414 
keeping with this concept, cDC2 expansion was potentiated in aged Ptpn22-/- mice (Supplementary 415 
Figure 1E) and as such changes to the balance of activating:inhibitory cells in vivo could alter cDC2 416 
dependent responses that trigger the breaking of immune tolerance. Future work will be required to 417 
confirm the link between early expansion of cDC2 and autoimmunity. 418 
In summary, our findings uncover PTPN22 as a selective regulatory checkpoint required to maintain 419 
cDC2 homeostasis, and suggest that early perturbation of DC homeostasis may be a trigger for the 420 
onset of autoimmunity. 421 
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 634 
11 Figure Legends 635 
Figure 1. PTPN22 negatively regulates ESAMHI cDC2 homeostasis. (A-D) Spleens of 2-4-month 636 
age matched wild type (WT) and Ptpn22-/- mice were evaluated for cDC subsets by flow cytometry, 637 
gated on: live, singlet, lin- (CD3, CD19, B220, Ly6C/G, NK1.1, Ter119), CD11c+MHCcII I-Ab+ and 638 
then CD8+ vs SIRP𝛼+ (A) Representative flow cytometry plot analysis of cDC subsets. (B) The 639 
proportion of CD11c+I-Ab+ cDC, (C) the proportion of CD8+ cDC1 and SIRP𝛼+ cDC2s, (D) the 640 
number of cDC, cDC1 and cDC2 per spleen. N=12-15 mice per genotype from >3 independent 641 
experiments. (E,F) Spleens of 2-4 month age matched wild type (WT) and Ptpn22-/- mice were 642 
evaluated for cDC subsets by flow cytometry, gated on: live, singlet, lin- (CD3, CD19, B220, 643 
Ly6C/G, NK1.1, Ter119), CD11c+MHCcII I-Ab+ , CD8-CD11b+, ESAM vs CD4. Representative 644 
flow cytometry plot analysis of cDC subsets (E) and the frequency of CD11b +DC2 ESAM+/- CD4+/- 645 
subsets per spleen (F). N=6 mice/genotype from 2 independent experiments. (G) Splenic cDC1 and 646 
cDC2 within pre-wean (3 weeks) and (H) post wean (4 weeks) WT and Ptpn22-/- mice. N=4 647 
mice/genotype. (I-K) Lymph node resident and migratory cDC subsets within 2-4-month age 648 
matched WT and Ptpn22-/- mice. Determined by flow cytometry gating on: singlet, live, lin- CD11c+ 649 
MHCcII I-AbInt (resident DC) or CD11c+ MHCcII I-AbHigh (migratory DC), and then CD8α (cDC1) 650 
vs CD11b+ (cDC2). (I) Representative flow cytometry plots. (J) Frequency of resident and migratory 651 
cDC and (K) frequency of resident and migratory cDC1 and cDC2; N=10 mice/genotype from 3 652 
independent experiments. Each point represents an individual mouse; bars represent mean, NS = not 653 
significant, *p<0.05, **p<0.01, ***p<0.001, determined by unpaired T-test.  654 
 655 
Figure 2. PTPN22 regulates cDC2 homeostasis in a DC intrinsic manner. (A-D) Lethally 656 
irradiated CD45.1/2 recipient mice received a 1:1 ratio of WT CD45.1 : WT or Ptpn22-/- CD45.2 657 
bone marrow (i.v). After 8 weeks spleens of recipient mice were evaluated for cDC subsets and the 658 
ratio of CD45.1:CD45.2 within each subset was determined by flow cytometry gating on: live, 659 
singlet, lin- CD11c+, MHCcII I-Ab+ and then CD8+ vs SIRP𝛼+ CD45.1+ vsCD45.2+. (A) Experiment 660 
schematic, (B) representative flow cytometry staining gated on either cDC2 (left) or cDC1 (right) 661 
subsets. (C,D) The ratio of CD45.1:CD45.2 within cDC1 and cDC2 subsets calculated relative to the 662 
input ratio. N=5-6 mice/genotype, one experiment of two. (E) Lethally irradiated wild type (WT) 663 
CD45.1/2 mice received a 1:1 ratio of WT CD45.1: dLckCre- or dLckCre+ (Ptpn22-/-) CD45.2 bone 664 
marrow (i.v). After 8 weeks spleens of recipient CD45.1/2 mice were evaluated for cDC subsets and 665 
the ratio of CD45.1:CD45.2 within each subset was determined by flow cytometry relative to the 666 
input ratio, N=3-4 mice/genotype. (F) WT CD45.1 bone marrow was transferred i.v into WT or 667 
Ptpn22-/- CD45.2 recipient mice and after 6 days the spleens of recipient mice were evaluated for the 668 
number of CD45.1 cDC1 and cDC2 by flow cytometry. (F) Schematic of experiment (G) N=9 669 
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mice/genotype, two independent experiments. Each point represents an individual mouse; bars 670 
represent mean and standard deviation, NS = not significant, ****p<0.0001 determined by unpaired 671 
T-test. 672 
Figure 3. PTPN22 regulates DC2 proliferation. (A) Bone marrow from wild type (WT) or Ptpn22-673 
/- mice cultured in the presence of Flt3L for 8 days (Flt3L-BMDC). At day 8 the proportion and 674 
number of CD24+ cDC1 and SIRPα+ cDC2 were determined by flow cytometry. N=6 mice per 675 
genotype from 6 independent experiments. (B) The frequency of live splenic cDC1 and cDC2 from 676 
WT and Ptpn22-/- measured 3 days after i.v immunization with 5-flurouracil or DMSO control. N=3-677 
4 mice per group. (C,D) The percentage of splenic cDC1 and cDC2 within BrDU- and BrDU+ 678 
populations within BrDU treated WT and Ptpn22-/- mice. (C) Representative flow plots of analysis, 679 
quantified in (D). N=3 mice per genotype. (E,F) Ki67 and DAPI expression within splenic cDC1 and 680 
cDC2 subsets from WT and Ptpn22-/- spleens. (E) Representative flow plot analysis and quantified in 681 
(F). N=8 mice per genotype. (A,B,D,F) Each point represents an individual mouse; bars represent 682 
mean and standard deviation. NS = not significant, (A-F)  *p<0.05, determined by unpaired T-test. 683 
NS = not significant, *p<0.05, **p<0.01, ****p<0.0001.  684 
Figure 4. Ptpn22619W conferred cDC2 expansion enhances T cell proliferation and TFH. (A,B) 685 
Spleens of 2-4 month age matched WT and Ptpn22619W mice were evaluated for cDC subsets by flow 686 
cytometry (A) number of cDC1 and cDC2 per spleen (B) number of ESAM- vs ESAM+ cDC2 per 687 
spleen. (A,B) N=10 mice per genotype. (C) Mice were immunized i.v. with PBS or SRBC and after 4 688 
hours splenic cDC2 were assessed for cell surface CD86 expression by flow cytometry. N=4 or 10 689 
mice/group. (D-H) CD45.1+CD4+ OT-II T cells were transferred i.v into recipient mice. The 690 
following day mice received i.v 33D1-ovalbumin in the presence or absence of sheep RBC (SRBC). 691 
After 3 days CD45.1+ CD4+ Vα2Vβ5+ T cells were evaluated for CTV dilution and CXCR5+PD-1+ T 692 
follicular helper cell (TFH) by flow cytometry. Representative plots of CTV dilution (D) and TFH 693 
induction (E) in the presence or absence of SRBC. (F-H) OT-II proliferation and TFH induction 694 
within WT and Ptpn22619W recipient mice determined by flow cytometry. (F) The number of 695 
proliferating CD45.1+ CD4+ Vα2Vβ5+ OT-II T cells. (G) The frequency of CD45.1+ 696 
Vα2Vβ5+CD4+PD-1+CXCR5+ TFH per spleen. (H) The number of CD45.1+ Vα2Vβ5+CD4+PD-697 
1+CXCR5+ TFH per spleen. (F-H) N=10 mice/genotype. Each point represents an individual mouse, 698 
bars represent mean; error bars represent s.e.m. (A-H) *p<0.05, ****p<0.0001 determined by 699 
unpaired T-test. 700 
